Related references
Note: Only part of the references are listed.Mendelian randomization in cardiometabolic disease: challenges in evaluating causality
Michael V. Holmes et al.
NATURE REVIEWS CARDIOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The druggable genome and support for target identification and validation in drug development
Chris Finan et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Leveraging human genetics to guide drug target discovery
Nathan O. Stitziel et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2017)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study
Amand F. Schmidt et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Genetically predicted 17beta-estradiol and cardiovascular risk factors in women: a Mendelian randomization analysis using young women in Hong Kong and older women in the Guangzhou Biobank Cohort Study
Shiu Lun Au Yeung et al.
ANNALS OF EPIDEMIOLOGY (2016)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine
Joshua C. Denny et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS, VOL 17 (2016)
Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator
Jack Bowden et al.
GENETIC EPIDEMIOLOGY (2016)
Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions A Systematic Review and Meta-analysis
Michael G. Silverman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Association Between Low-Density Lipoprotein Cholesterol-Lowering Genetic Variants and Risk of Type 2 Diabetes A Meta-analysis
Luca A. Lotta et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Beyond Mendelian randomization: how to interpret evidence of shared genetic predictors
Stephen Burgess et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
The genetics of drug efficacy: opportunities and challenges
Matthew R. Nelson et al.
NATURE REVIEWS GENETICS (2016)
Unravelling the human genome-phenome relationship using phenome-wide association studies
William S. Bush et al.
NATURE REVIEWS GENETICS (2016)
Variation in PCSK9 and HMGCR and Risk of Cardiovascular Disease and Diabetes
Brian A. Ference et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Beyond muscle destruction: a systematic review of rhabdomyolysis for clinical practice
Luis O. Chavez et al.
CRITICAL CARE (2016)
Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression
Jack Bowden et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2015)
HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials
Daniel I. Swerdlow et al.
LANCET (2015)
Opportunities for drug repositioning from phenome-wide association studies
Majid Rastegar-Mojarad et al.
NATURE BIOTECHNOLOGY (2015)
The Genotype-Tissue Expression (GTEx) pilot analysis: Multitissue gene regulation in humans
Kristin G. Ardlie et al.
SCIENCE (2015)
MR-PheWAS: hypothesis prioritization among potential causal effects of body mass index on many outcomes, using Mendelian randomization
Louise A. C. Millard et al.
SCIENTIFIC REPORTS (2015)
Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis
Daniel F. Freitag et al.
LANCET DIABETES & ENDOCRINOLOGY (2015)
Novel gene variants predict serum levels of the cytokines IL-18 and IL-1ra in older adults
A. M. Matteini et al.
CYTOKINE (2014)
Mendelian randomization: genetic anchors for causal inference in epidemiological studies
George Davey Smith et al.
HUMAN MOLECULAR GENETICS (2014)
Discovery and refinement of loci associated with lipid levels
Cristen J. Willer et al.
NATURE GENETICS (2013)
Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions
Ann K. Daly
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 52 (2012)
Novel Data-Mining Methodologies for Adverse Drug Event Discovery and Analysis
R. Harpaz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
Benjamin F. Voight et al.
LANCET (2012)
Use of genome-wide association studies for drug repositioning
Philippe Sanseau et al.
NATURE BIOTECHNOLOGY (2012)
Drug repositioning for Alzheimer's disease
Anne Corbett et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Use of genetic markers and gene-diet interactions for interrogating population-level causal influences of diet on health
George Davey Smith
GENES AND NUTRITION (2011)
Deconstructing the Drug Development Process: The New Face of Innovation
K. I. Kaitin
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials
Naveed Sattar et al.
LANCET (2010)
Genome-wide association studies in pharmacogenomics
Ann K. Daly
NATURE REVIEWS GENETICS (2010)
Confounding Control in Healthcare Database Research Challenges and Potential Approaches
M. Alan Brookhart et al.
MEDICAL CARE (2010)
Narrative Review: Statin-Related Myopathy
Tisha R. Joy et al.
ANNALS OF INTERNAL MEDICINE (2009)
Mendelian Randomization: How It Can-and Cannot-Help Confirm Causal Relations between Nutrition and Cancer
Arthur Schatzkin et al.
CANCER PREVENTION RESEARCH (2009)
Quantitative assessment of unobserved confounding is mandatory in nonrandomized intervention studies
R. H. H. Groenwold et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2009)
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans
Sekar Kathiresan et al.
NATURE GENETICS (2008)
Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology
Debbie A. Lawlor et al.
STATISTICS IN MEDICINE (2008)
Clustered environments and randomized genes: A fundamental distinction between conventional and genetic epidemiology
George Davey Smith et al.
PLOS MEDICINE (2007)
The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis
Charles R. Harper et al.
CURRENT OPINION IN LIPIDOLOGY (2007)
Drug repositioning: Identifying and developing new uses for existing drugs
TT Ashburn et al.
NATURE REVIEWS DRUG DISCOVERY (2004)
Socioeconomic position and hormone replacement therapy use: Explaining the discrepancy in evidence from observational and randomized controlled trials
DA Lawlor et al.
AMERICAN JOURNAL OF PUBLIC HEALTH (2004)
Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs
DJ Graham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Trends in development and approval times for new therapeutics in the United States
JM Reichert
NATURE REVIEWS DRUG DISCOVERY (2003)
Statin effects beyond lipid lowering-are they clinically relevant?
PO Bonetti et al.
EUROPEAN HEART JOURNAL (2003)
'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease?
GD Smith et al.
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY (2003)
A model for the future conduct of pharmacovigilance
PC Waller et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2003)
Cerivastatin and reports of fatal rhabdomyolysis.
JA Staffa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Rapid effects on vascular function after initiation and withdrawal of atorvastatin in healthy, normocholesterolemic men
U Laufs et al.
AMERICAN JOURNAL OF CARDIOLOGY (2001)
Rhabdomyolysis and HMG-CoA reductase inhibitors
MA Omar et al.
ANNALS OF PHARMACOTHERAPY (2001)
Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, improves endothelial function in elderly diabetic patients within 3 days
T Tsunekawa et al.
CIRCULATION (2001)
Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease
AM Lefer et al.
CARDIOVASCULAR RESEARCH (2001)
Share Paper
